Roche Just Paid $1.53 Billion for a Drug That's Never Been in a Human
Roche just locked up exclusive global rights to a preclinical trispecific antibody from Chinese biotech Simcere Zaiming for up to $1.53 billion. The drug has never been tested in a human, but it targets B cells in a way Roche's legacy blockbusters can't.
The Most Expensive Science Experiment You've Never Heard Of
Imagine paying $1.53 billion for a house that hasn't been built yet. No foundation. No blueprints approved by the city. Just a really, really promising plot of land.
That's essentially what Roche just did. The Swiss pharma giant locked up exclusive global rights to SIM0660, a novel antibody from Chinese biotech Simcere Zaiming, in a deal worth up to $1.53 billion. The catch? The drug is still preclinical. It has never been tested in a single human being.
So either Roche knows something the rest of us don't, or the B-cell therapy market is so hot that Big Pharma is willing to write nine-figure checks on a hypothesis.
Let's figure out which one it is.
What Roche Is Actually Buying
SIM0660 is what's called a trispecific antibody, which is a mouthful that essentially means it can grab onto three different targets at once. Think of it like a molecular Swiss Army knife. Most antibodies in this space bind one or two things; this one binds three: CD79a, CD19, and CD3.
The first two (CD79a and CD19) are proteins found on B cells, a type of immune cell that goes haywire in blood cancers and autoimmune diseases like lupus. The third target, CD3, sits on T cells, the immune system's assassins. By linking all three, SIM0660 is designed to redirect T cells to hunt down and kill rogue B cells while (hopefully) keeping the inflammatory side effects in check.
If that sounds like a next-generation upgrade to Roche's existing playbook, that's because it is. Roche built a dynasty on B-cell therapies: rituximab (Rituxan) for cancer, ocrelizumab (Ocrevus) for multiple sclerosis. Those drugs target a protein called CD20. SIM0660 goes after different addresses on the same cell, which could matter enormously for patients whose disease has already learned to dodge CD20-targeted treatments.
Follow the Money
The $1.53 billion headline is impressive, but let's look under the hood. Roche is paying . That's the real cash on the table today. The remaining roughly $1.46 billion is all milestones: payments that only kick in if the drug hits specific development, regulatory, and commercial targets down the road. Simcere also gets on any future sales.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
$75 million upfront
tiered royalties up to the double digits
In other words, Roche structured this like a performance bonus. The upfront is less than 5% of the total deal value. If SIM0660 flames out in early trials (and preclinical assets fail more often than they succeed), Roche walks away having spent $75 million on an expensive lesson. For a company that posted over $60 billion in revenue last year, that's a rounding error.
But if it works? Roche gets a potentially best-in-class B-cell weapon for both oncology and autoimmune disease, two of the biggest markets in medicine.
Why China Keeps Showing Up in These Deals
This isn't a one-off. Western pharma companies have been on a shopping spree for Chinese-originated immunology assets, and the pace is accelerating fast.
In just the first half of 2025, companies signed 14 licensing agreements worth up to $18.3 billion for Chinese biotech assets. That's up from just two deals in the same period a year earlier. The total value of China-to-international partnerships hit $48.5 billion in H1 2025 alone, surpassing all of 2024.
The deals keep getting bigger, too. UCB paid $80 million in upfront and near-term milestone payments (with a $1.2 billion total) for Antengene's CD19xCD3 bispecific targeting B-cell-related autoimmune diseases. Zenas grabbed a BTK inhibitor from InnoCare for up to $100 million in upfront and near-term payments and a total exceeding $2 billion. Even Simcere itself has been busy: Ipsen licensed Simcere Zaiming's LRRC15-targeting ADC for up to $1.06 billion in 2025, and Boehringer Ingelheim signed a roughly $1.05 billion deal for a Simcere bispecific targeting inflammatory bowel disease.
The pattern is clear. Chinese biotechs are building differentiated molecules at a lower cost, and Western pharma is happy to pay a premium for global rights. It's outsourced R&D with a billion-dollar ceiling.
Roche's Bigger Chess Game
Zoom out, and this deal makes more sense as part of Roche's broader strategy than as a standalone bet. The company isn't trying to replace rituximab and ocrelizumab; it's trying to stack new modalities around them like armor plating.
In hematology, Roche already has glofitamab and mosunetuzumab (CD20xCD3 bispecifics), polatuzumab vedotin (a CD79b antibody-drug conjugate), and venetoclax for certain blood cancers. Adding SIM0660's triple-targeting approach gives Roche another card to play, especially in patients who've already cycled through existing options.
On the autoimmune side, the logic is even more compelling. B-cell depletion is becoming a white-hot area in immunology. If you can selectively wipe out the B cells causing disease without nuking the entire immune system, you've got something potentially transformative for conditions like lupus, rheumatoid arthritis, and myasthenia gravis.
SIM0660 was Roche's second sizable licensing deal in just over a week, which suggests this isn't opportunistic deal-making. It's a deliberate campaign to reload the pipeline through external innovation.
The Risk Nobody's Talking About
Let's be honest about the elephant in the room: preclinical assets fail all the time. The historical success rate for drugs going from preclinical to approval is around 0.4%. SIM0660 hasn't even entered a Phase 1 trial yet.
Trispecific antibodies are also a relatively new concept. The engineering is elegant on paper, but translating that into a drug that's safe, effective, and manufacturable at scale is a completely different challenge. The claim that SIM0660 can engage three targets while limiting cytokine release syndrome (the dangerous inflammatory reaction that plagues many T-cell engagers) is exactly the kind of promise that needs to survive contact with actual human biology.
Simcere's track record offers some comfort. Its recent partnerships with Ipsen, AbbVie, and Boehringer Ingelheim suggest its science is being taken seriously by multiple global players, not just Roche.
The Bottom Line
Roche paid $75 million today for the right to potentially spend $1.53 billion later on a drug that doesn't exist yet in any clinic. That sounds wild until you realize the B-cell therapy market is one of the most valuable franchises in all of pharma, and Roche's legacy products won't stay on top forever.
The deal is a calculated bet: low upfront risk, enormous upside if SIM0660 delivers on its triple-targeting promise. For Simcere Zaiming, it's validation that Chinese biotech innovation can command billion-dollar price tags from the world's biggest drugmakers.
For everyone else watching, the message is simple. The era of Big Pharma doing all its own R&D is over. The best science can come from anywhere, and the companies willing to write early checks on unproven but differentiated assets are the ones shaping the next decade of medicine.
Whether SIM0660 ever treats a patient remains to be seen. But Roche clearly decided it couldn't afford to wait and find out.
Clinical & Regulatory
4 min read
The Government Wants an AI Doctor for Your Heart
ARPA-H just bet $62.7 million that an AI can manage heart failure patients around the clock, prescribing drugs and ordering tests without waiting for a doctor. If it works, it could reshape how we treat the fastest-growing heart condition in America.
